CIK 0001720580 · Non-accelerated filer<br>Smaller reporting company
Adicet Bio, Inc.
Sign in to watch- Ticker
- ACET
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 26
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813305277
- Phone
- 617-482-2333
- Business address
- 131 DARTMOUTH STREET, 3RD FLOOR, BOSTON, MA, 02116
- Former names
- resTORbio, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-08-14 | Schor Chen President & CEO | Returned to the company · Stock Option (Right to Buy) | −384,900 | 0 | ||
| 2023-08-14 | Schor Chen President & CEO | Grant or award · Stock Option (Right to Buy) | +384,900 | 384,900 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −113,652 | 0 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +113,652 | 113,652 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −77,269 | 0 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +77,269 | 77,269 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −73,964 | 0 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +73,964 | 73,964 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −26,625 | 0 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +26,625 | 26,625 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −125,000 | 0 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −117,200 | 0 | ||
| 2023-08-14 | Galimi Francesco SVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +117,200 | 117,200 | ||
| 2023-08-14 | Aftab Blake Chief Scientific Officer | Returned to the company · Stock Option (Right to Buy) | −50,000 | 0 | ||
| 2023-08-14 | Aftab Blake Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2023-08-14 | Aftab Blake Chief Scientific Officer | Returned to the company · Stock Option (Right to Buy) | −56,612 | 0 | ||
| 2023-08-14 | Aftab Blake Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +56,612 | 56,612 | ||
| 2023-08-14 | Aftab Blake Chief Scientific Officer | Returned to the company · Stock Option (Right to Buy) | −125,000 | 0 | ||
| 2023-08-14 | Aftab Blake Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 |
Page 9 of 15 · 298 trades